Deadline: 2-May-25
Pfizer is pleased to announce the Competitive Grant Program to support initiatives that will improve the quality of care or quality of healthcare services for patients with ALK+ Non-Small Cell Lung Cancer (NSCLC) through the incorporation of AI applications and clinical tools.
At Pfizer it’s the mission to be the premier, innovative biopharmaceutical company, making breakthroughs that change patients’ lives. Good health is vital to all of them and finding sustainable solutions to the most pressing health care challenges of the world cannot wait. That’s why they at Pfizer are committed to applying science and the global resources to improve health and well-being at every stage of life. They strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.
Area of Interest
- General Area of Interest for this RFP:
- Projects that will be considered for Pfizer support may fall into 1 of 2 different grant types:
- Investigator-Sponsored/General Research designed to develop and study the effectiveness of a new AI-based tool or strategy in a pilot group of ALK+ NSCLC patients; or
- Quality Improvement (QI) projects aimed at translating existing and already validated AI-based tools or strategies into everyday clinical practice for the benefit of all ALK+ NSCLC patients coming through that organization or institution.
- Projects that will be considered for Pfizer support may fall into 1 of 2 different grant types:
- Areas of interest include:
- Improve histological and molecular biomarker testing practices in NSCLC.
- Development of standard workflows for biomarker testing.
- Optimal management of the most common pharmacological side effects.
- Initiatives to improve patients’ quality of life and enhance the collection and utilization of PROs.
- Implementing tools for sharing experiences between groups of patients and between patients and caregivers to optimize their diagnostic and/or therapeutic awareness and opportunities.
Funding Information
- Individual projects requesting up to €90,000 will be considered.
- The total available budget related to this RFP is €180,000.
Duration
- Projects should start in 2025 with a project duration of up to 2 years.
Project Types
- Organizations are invited to submit proposals for either General Research or Quality Improvement projects that will implement innovative AI-based approaches to improve the quality of care for ALK+ NSCLC patients. Projects should aim to improve patient care at any point from diagnosis to clinical experience including addressing the physical, social, or emotional side effects of therapies. Projects may include optimizination of the collection and evaluation of patient-reported outcomes (PROs).
Geographic Scope
Eligibility Criteria
- The following may apply: public healthcare bodies (hospitals, Aziende Sanitarie Locali [ASLs], universities, Istituto di Ricovero e Cura a Carattere Scientifico [IRCCS] or accredited private hospitals that are involved in the care of oncological patients.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).
- The Project Lead/PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. They strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.
For more information, visit Pfizer.